SubscribeLogin
Pipelinereview image

News from Pipelinereview

Information about Pipelinereview

Where is Pipelinereview located?Pipelinereview's Website

Media Bias Ratings

Do you diasgree?
Edit bias
Learn more about Media Bias Ratings.

Factuality

Learn more about  Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about  Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top Pipelinereview News

Why Are Teva And Sanofi Stocks Trading Higher On Tuesday? - Teva Pharmaceutical Indus (NYSE:TEVA), Sanofi (NASDAQ:SNY)
Business

Why Are Teva And Sanofi Stocks Trading Higher On Tuesday? - Teva Pharmaceutical Indus (NYSE:TEVA), Sanofi (NASDAQ:SNY)

67% Center coverage: 3 sources
On Tuesday, Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) and Sanofi SA’s (NASDAQ:SNY) Phase 2b RELIEVE UCCD study met its primary endpoints in patients with ulcerative colitis (UC) and Crohn’s disease (CD). RELIEVE UCCD investigated duvakitug (TEV’574/SAR447189), a human IgG1-λ2 monoclonal antibody targeting TL1A, for moderate-to-severe inflammatory bowel disease (IBD). In the RELIEVE UCCD study, 36.2% (low-dose) and 47.8% (high-dose) of pati…See the Story
Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT™ (cosibelimab-ipdl) - Fortress Biotech (NASDAQ:FBIO), Checkpoint Therapeutics (NASDAQ:CKPT)
Cancer · United States

Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT™ (cosibelimab-ipdl) - Fortress Biotech (NASDAQ:FBIO), Checkpoint Therapeutics (NASDAQ:CKPT)

67% Center coverage: 3 sources
WALTHAM, Mass., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. ("Checkpoint") (NASDAQ:CKPT), today announced that the U.S. Food and Drug Administration ("FDA") has approved UNLOXCYT™ (cosibelimab-ipdl) for the treatment of adults with metastatic cutaneous squamous cell carcinoma ("cSCC") or locally advanced cSCC who are not candidates for curative surgery or curative radiation. UNLOXCYT is the first and only programmed death l…See the Story
FDA approves Celltrion's biosimilar of J&J's Stelara (JNJ:NYSE)
Johnson & Johnson · United States

FDA approves Celltrion's biosimilar of J&J's Stelara (JNJ:NYSE)

100% Right coverage: 1 sources
The FDA has approved Steqeyma, a biosimilar of J&J's Stelara, for the treatment of Crohn's disease, ulcerative colitis, psoriasis, and psoriatic arthritis. Read more here.See the Story

Latest News Stories

You've scrolled to the bottom of the feed, there are no more stories.
Trending Topics
App Store IconPlay Store Icon
CompanyAboutHistoryMissionBlogTestimonialsGroup SubscriptionsSubscribeGiftFree TrialCareersAffiliates
HelpHelp CenterFAQContact UsFor Educators/LibrariesMedia Bias RatingsOwnership and Factuality RatingsReferral CodeNews SourcesTopics
ToolsAppBrowser ExtensionDaily NewsletterBlindspot Report NewsletterBurst Your Bubble NewsletterTimelines
DonatePrivacy PolicyManage CookiesTerms and Conditions
© 2024 Snapwise Inc
News
For You
Search
BlindspotLocal